2022
DOI: 10.1007/s00432-022-04298-2
|View full text |Cite
|
Sign up to set email alerts
|

Characterization of PDL1 enhanced siRNA/albumin liposome for effective therapeutic function in lung cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 38 publications
0
1
0
Order By: Relevance
“…The fabrication process is complicated and expensive, which restricts accessibility. Liposomes’ efficacy in targeting tumors is hindered by the variability of tumor blood vessels and quick removal from the bloodstream by the mononuclear phagocyte system, which reduces drug delivery to the tumor site [ 10 ]. Cancer cells can develop resistance mechanisms against medications, which can impact the effectiveness of treatment [ 11 ].…”
Section: Introductionmentioning
confidence: 99%
“…The fabrication process is complicated and expensive, which restricts accessibility. Liposomes’ efficacy in targeting tumors is hindered by the variability of tumor blood vessels and quick removal from the bloodstream by the mononuclear phagocyte system, which reduces drug delivery to the tumor site [ 10 ]. Cancer cells can develop resistance mechanisms against medications, which can impact the effectiveness of treatment [ 11 ].…”
Section: Introductionmentioning
confidence: 99%